ZA200808420B - Pharmaceutical composition comprising anti-mirna anti-sense oligonucleotides - Google Patents
Pharmaceutical composition comprising anti-mirna anti-sense oligonucleotidesInfo
- Publication number
- ZA200808420B ZA200808420B ZA200808420A ZA200808420A ZA200808420B ZA 200808420 B ZA200808420 B ZA 200808420B ZA 200808420 A ZA200808420 A ZA 200808420A ZA 200808420 A ZA200808420 A ZA 200808420A ZA 200808420 B ZA200808420 B ZA 200808420B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical composition
- mirna
- sense oligonucleotides
- oligonucleotides
- sense
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200600478 | 2006-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200808420B true ZA200808420B (en) | 2009-08-26 |
Family
ID=36746645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200808420A ZA200808420B (en) | 2006-04-03 | 2008-10-02 | Pharmaceutical composition comprising anti-mirna anti-sense oligonucleotides |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101437942A (en) |
NZ (1) | NZ594605A (en) |
ZA (1) | ZA200808420B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102311956B (en) * | 2011-09-20 | 2012-11-21 | 浙江大学 | Specific base modification antisense nucleotide chain and application thereof |
CN105087477A (en) * | 2015-05-21 | 2015-11-25 | 王松灵 | Application of mesenchymal stem cell modified by miR-21 antisense nucleotide |
US20180161357A1 (en) * | 2015-06-05 | 2018-06-14 | MiRagen Therapeutics, Inc. | Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als) |
EP3303590A4 (en) * | 2015-06-05 | 2019-01-02 | Miragen Therapeutics, Inc. | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) |
CN108025017A (en) * | 2015-09-22 | 2018-05-11 | 米拉根医疗股份有限公司 | MiR-19 conditioning agents and application thereof |
WO2017132945A1 (en) * | 2016-02-04 | 2017-08-10 | 中国科学技术大学 | Design and application of mirancer molecule |
WO2020038968A1 (en) * | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
CN115337322B (en) * | 2021-05-13 | 2024-04-19 | 南京大学 | Application of RNA in preparation of products for treating pulmonary fibrosis related diseases |
-
2007
- 2007-03-30 NZ NZ594605A patent/NZ594605A/en not_active IP Right Cessation
- 2007-03-30 CN CNA2007800158808A patent/CN101437942A/en active Pending
-
2008
- 2008-10-02 ZA ZA200808420A patent/ZA200808420B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ594605A (en) | 2013-03-28 |
CN101437942A (en) | 2009-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL194007A0 (en) | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides | |
SG10201406016SA (en) | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides | |
IL198911A0 (en) | Drug delivery | |
HK1125295A1 (en) | Microtablet-based pharmaceutical preparation | |
LT3984528T (en) | Pharmaceutical compositions comprising nilotinib | |
EP2001498A4 (en) | Pharmaceutical compositions | |
IL194176A0 (en) | Pharmaceutical compositions | |
GB0713625D0 (en) | Pharmaceutical compositions | |
ZA200901175B (en) | Drug dispenser | |
PL2124556T3 (en) | Pharmaceutical compositions | |
GB0614586D0 (en) | Pharmaceutical Formulation | |
EP2010162A4 (en) | Drug delivery composition | |
ZA200901093B (en) | Drug dispenser | |
ZA200808420B (en) | Pharmaceutical composition comprising anti-mirna anti-sense oligonucleotides | |
ZA200807486B (en) | Medicament formulations comprising fluoroquinolones | |
GB0625783D0 (en) | Medicament | |
GB0614365D0 (en) | Pharmaceutical compositions and their use | |
EP2124959A4 (en) | Pharmaceutical composition | |
IL198160A0 (en) | Pharmaceutical formulations | |
GB0615064D0 (en) | Medicament | |
HU0600097D0 (en) | Pharmaceutical composition comprising tacrolimus | |
EP2197454A4 (en) | Pharmaceutical compositions for administering oligonucleotides | |
GB0615814D0 (en) | Medicament | |
ZA200708369B (en) | Medicament | |
GB0623402D0 (en) | Medicament dispenser |